p73 and p53 pathway in human breast cancers [9]

Journal of Clinical Oncology

Volumn 25, Issue 11, 2007, Pages 1451-1453

  Bozzetti, Cecilia ^a   Nizzoli, Rita ^a   Musolino, Antonino ^a   Martella, Eugenia M ^b   Crafa, Pellegrino ^b   Lagrasta, Costanza A ^b   Camisa, Roberta ^a   Bonati, Antonio ^a,c   Lunghi, Paolo ^c   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN P53; PROTEIN P73; TRANSCRIPTION FACTOR E2F1;

BREAST CANCER; CARCINOGENESIS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 34248194233     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.2023     Document Type: Letter

References (14)

1. Dominguez G, Garcia JM, Pena C, et al: DeltaTAp73 upregulation correlates with poor prognosis in human tumors: Putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 24:805-815, 2006
2. Inoue T, Stuart J, Leno R, et al: Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem 277:15053-15060, 2002
3. Tannapfel A, Engeland K, Weinans L, et al: Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer 80:1069-1074, 1999
4. Tannapfel A, Wasner M, Krause K, et al: Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 91:1154-1158, 1999
5. Chen YK, Huse SS, Lin LM: Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas. Clin Otolaryngol Allied Sci 28:451-455, 2003
6. Uramoto H, Sugio K, Oyama T, et al: Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10:6905-6911, 2004
7. Frasca F, Vella V, Aloisi A, et al: P73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 63:5829-5837, 2003
8. Lunghi P, Costanzo A, Levrero M, et al: Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. Blood 104:519-525, 2004
9. Rizzo MG, Giombini E, Diverio D, et al: Analysis of p73 expression pattern in acute myeloid leukemias: Lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 18:1804-1809, 2004
10. Lunghi P, Costanzo A, Salvatore L, et al: MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 107: 4549-4553, 2006
11. Hu G, Zhang W, Deisseroth AB: p53 gene mutations in acute myelogenous leukaemia. Br J Haematol 81:489-494, 1992
12. Bueso-Ramos CE, Yang Y, deLeon E, et al: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617-2623, 1993
13. Kojima K, Konopleva M, Samudio IJ, et al: MDM2 antagonists induce p53-dependent apoptosis in AML: Implications for leukemia therapy. Blood 106:3150-3159, 2005
14. Zaika AI, Slade N, Erster SH, et al: DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196:765-780, 2002